Method of reducing cyclophosphamide induced hemorrhagic cystitis

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514369, 514922, 514974, 514 90, A61K 31425, A61K 4900

Patent

active

054477123

ABSTRACT:
A method is provided for reducing side effects caused by chemotherapeutic agents by administering to a patient in need thereof a therapeutically effective amount of a composition including L-2-oxothiazolidine-4-carboxylate specifically for reducing hemorrhagic cystitis in a patient at risk of same.

REFERENCES:
patent: 2712202 (1955-07-01), Hosler et al.
patent: 3737536 (1973-06-01), Sagner et al.
patent: 3755578 (1973-08-01), McFarland et al.
patent: 4175130 (1979-11-01), Yamanaka et al.
patent: 4335210 (1982-07-01), Meister et al.
patent: 4338315 (1982-07-01), Paget et al.
patent: 4398026 (1983-08-01), Takano
patent: 4420479 (1983-12-01), Morwick et al.
patent: 4434158 (1984-02-01), Meister
patent: 4438124 (1984-03-01), Meister
patent: 4563471 (1986-01-01), Satzinger et al.
patent: 4647453 (1987-03-01), Meisner
patent: 4647571 (1987-03-01), Meister
patent: 4665082 (1987-05-01), Meister et al.
patent: 4710489 (1987-12-01), Meister
patent: 4752618 (1988-07-01), Mascioli et al.
patent: 4775675 (1988-10-01), Gyorgydeak et al.
patent: 4780475 (1988-10-01), Cerra et al.
patent: 4784685 (1988-11-01), Meister
patent: 4791125 (1988-12-01), Clark
patent: 4798835 (1989-01-01), Krupp et al.
patent: 4839387 (1989-07-01), Poli
patent: 4868114 (1989-09-01), Nagasawa et al.
patent: 4879370 (1989-11-01), Meister
patent: 4963577 (1990-10-01), Schorlemmer et al.
patent: 5002953 (1991-03-01), Hindley
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5039609 (1991-08-01), Klein
patent: 5053387 (1991-10-01), Alexander
patent: 5055446 (1991-10-01), Alexander et al.
patent: 5089268 (1992-02-01), Katz
patent: 5095027 (1992-03-01), Goldberg et al.
patent: 5158883 (1992-10-01), Griffith
patent: 5208249 (1993-05-01), Rowe et al.
patent: 5214062 (1993-05-01), Mark et al.
Mitchell et al., Br. J. Cancer Suppl. VIII (1987 Jun.) pp. 96-104. Ref: 38.
Bounous, et al., Immunoenhancing Property of Dietary Whey Protein in Mice, Role of Glutathoine, Clinical Investigative Medicine, vol. 12, No. 4, pp. 154-161. 1989.
Suthanthiran, et al., Glutathione Regulates Activation-Dependent DNA Synthesis in High Purified Normal Human T Lymphocytes Stimulated via the CD2 and CD3 Antigens, Proc. of National Academic Sciences, vol. 37, May 1990, pp. 3343-3347.
Chung, et al., L-2-Oxothiazolidine-4-Carboxylate as a cysteine Precursor: Efficacy for Growth and Hepatic Glutatione Synthesis in Chicks and Rats, American Institute of Nutrition, pp. 158-165. 1989.
Mandel, et al. Intracellular Gluthathione in the Protection from Anoxic Injury in Renal Proximal Tubles, J. Clin. Invest., 1990 vol. 85, No. 2, pp. 316-324.
Chang, et al., Cytoprotective Effect of Reduced Glutathione in Arsenical-Induced Endothelial Cell Injury, Toxicology, 1991, vol. 69, No. 1, pp. 101-110.
Moslen, Protection by L-2-Oxothiazolidine-4-Carboxylate, a Cysteine Prodrug, Against 1,1-Dichlorethylene Hepatotoxicity in Rats is Associated with Decreased in Toxin Metabolism and Cytochrome P-450, J. Pharmacol. Exp. Ther., vol. 248, No. 1, pp. 157-163. 1989.
Cretton, et al., Catabolism of 3'-Axido-3'Deoxythymidine in Hepactocytes and Liver Microsomes, with Evidence of Formation of 3'-Amino-3'Deoxythymidine, a Highly Toxic Catabolite for Human Bone Marrow Cells, Molecular Pharmacology, Vo. 39, pp. 258-266. 1990.
Handlon, et al., Thiol Reduction of 3'-Aziodthymidine to 3'-Aminothymidine: Kinetics and Biomedical Implications, Pharmaceutical Research, vol. 5, No. 5, pp. 297-299, 1987.
Lamperth, et al. Abnormal Skeletal and Cardiac Muscle Mitochondria Induced by Zidovudine (AZT) in Human Muscle In vitro and in an Animal Model, Laboratory Investigation, vol. 65, No. 6, pp. 742-752. 1991.
Bone, et al., Definitions for Sepsis and Organ Failure, Critical Care Medicine, 1992, vol. 20, No. 6, pp. 724-725.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis, Critical Care Medicine, Jun. 1992, vol. 20, No. 6, pp. 864-874.
Kilbourn, et al., Inhibition of Interleukin-1-.alpha.-Induced nitric Oxide Synthase in Vascular Smooth Muscle and Full Reversal of Interleukin-1-.alpha. Induced Hypotension by N.sup..omega. -Amino-L-Arginine, Journal of the National Cancer Institute, Jul. 1, 1992, vol. 84, No. 13, pp. 1008-1016.
Osol, et al., EDs., Remington's Pharmaceutical Sciences, 1980, Sixteenth Edition.
W. Lucht et al, Prevention of Release of Granulocyte Aggregants into Sheep Lung Lymph Following Endotoxemia by N-Acetylcysteine, The American Journal of the Medical Sciences, vol. 294, No. 3, Sep. 1987, pp. 161-167.
G. Bernard et al, Effect of N-Acetylcysteine on the Pulmonary Response to Endotoxin in the Awake Sheep and Upon In Vitro Granulocyte Function, J. Clin. Invest., vol. 73, Jun. 1984, pp. 1772-1784.
A. Cantin et al, Normal Alveolar Epithelial Lining Fluid Contains High Levels of Glutathione, pp. 152-157. 1987.
L. Smith et al, Effect of Fasting on Hyperoxic Lung Injury in Mice, Am. Rev. Respir. Dis. 1990; 141:141-149.
J. Strausz et al, Oxygen Radical Production by Alveolar Inflammatory Cells in Idiopathic Pulmonary Fibrosis, Am. Rev. Respir. Dis. 1990; 141:124-128.
A. Cantin et al, Glutathione Deficiency in the Epithelial Lining Fluid of the Lower Respiratory Tract in Idiopathic Pulmonary Fibrosis, Am. Rev. Respir. Dis. 1989; 139:370-372.
Guarding Against Cellular Glutathione Deficiency, Nutrition Reviews, vol. 48, No. 9, Sep. 1990, pp. 346-348.
A. Cantin et al, Oxidants, Antioxidants and the Pathogenesis of Emphysema, Eur. J. Respir. Dis (1985) 66, Suppl. 139, pp. 7-17.
I. Cotgreave et al, Lung and Systemic Thiol Homeostasis During an Acute Lung Inflammation in the Rat, Toxicology, 50 (1988), pp. 331-343.
J. Sun et al, Effects of Buthionine Sulfoximine on the Development of Ozone-Induced Pulmonary Fibrosis, Experimental and Molecular Pathology 49 (1988), pp. 254-266.
S. Baldwin et al, Oxidant Activity in Expired Breath of Patients with Adult Respiratory Distress Syndrome, The Lancet, Jan. 4, 1986, pp. 11-14.
M. F. Tsan et al, Enhancement of Intracellular Glutathione Protects Endothelial Cells Against Oxidant Damage, Biochemical and Biophysical Research Communications, vol. 127, No. 1, Feb. 28, 1985, pp. 270-276.
M. F. Tsan et al, L-2-Oxothiazolidine-4-Carboxylate Protects Endothelial Cells Against Hyperocia-Induced Injury, Inflammation, vol. 12, No. 2, 1988, pp. 113-121.
P. H. S. Sporn et al, Complex Effects of In Vitro Hyperoxia on Alveolar Macrophage Arachidonic Acid Metabolism, American Journal of Respiratory Cell and Molecular Biology, vol. 2, No. 1, Jan. 1990, pp. 81-90.
M. A. Passero et al, L-2-Oxothiazolidine-4-Carboxylic Acid Increases Glutathione in Mouse Lung, A. Rev. Respir. Dis., vol. 133, 1986, p. A395.
Bellin, et al., Purification of Glycosaminoglycens from Bovine Follicular Fluid, J. Dairy Sci., Nov. 9, 1987, vol. 70, pp. 1913-1919.
Calvin, et al., Estimation and Manipulation of Glutathione Levels in Prepuberal Mouse Ovaries and Ova: Relevance to Sperm Nucleus Transformation in the Fertilized Egg, Gamete Research, 1986, vol. 14, pp. 165-275.
Gordon, et al., Applications of Micromanipulation to Human in Vitro Fertilization, Journal of In Vitro Fertilization and Embryo Transfer, 1988, vol. 5, No. 2, pp. 57-60.
Perreault, et al., Importance of Glutathione in the Acquisition and Maintenance of Sprem Nuclear Decondensing Activity in Maturing Hamster Oocytes, Developmental Biology, 1988, vol. 125, pp. 181-186.
Perreault, et al., The Timing of Hamster Sperm Nuclear Decondensation and Male Pronucleus Formation is Related to Sperm Nuclear Disulfide Bond Content, Biology of Reproduction, 1987, vol. 36, pp. 239-244.
Perreault, et al., The Role of Disulfide Bond Reduction During Mammalian Sperm Nuclear Decondensation in Vivo, Developmental Biology, 1984, vol. 101, pp. 160-167.
Reyes, et al., Heparin and Glutathione: Physiological Decondensing Agents of Human Sperm Nuclei, Gamete Research, 1989, vol. 23, pp. 39-47.
Zirkin, et al., In Vit

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method of reducing cyclophosphamide induced hemorrhagic cystitis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of reducing cyclophosphamide induced hemorrhagic cystitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing cyclophosphamide induced hemorrhagic cystitis will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-471124

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.